- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01721109
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen (STR) (Part A) and to evaluate the safety and tolerability of EVG/COBI/FTC/TDF STR through Week 48 (Part B) in HIV-1 infected, antiretroviral (ARV) treatment-naive adolescents.
A total of 50 adolescent participants (12 to < 18 years of age) will be enrolled to receive EVG/COBI/FTC/TDF as follows:
- Part A: Twelve to 16 eligible participants will be enrolled to evaluate steady-state PK, and confirm the dose, with the intent to enroll at least 4 participants 12 to < 15 and at least 4 participants 15 to < 18 years of age.
- Part B: Following confirmation of EVG exposure in at least 12 participants from Part A, 34 to 38 participants in addition to those enrolled in Part A will be enrolled to evaluate the safety, tolerability, and antiviral activity of EVG/COBI/FTC/TDF STR.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Oakland, California, Estados Unidos, 94609
- East Bay AIDS Center Medical Group
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33606
- University of South Florida - Department of Pediatrics
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
-
New York
-
Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
New York, New York, Estados Unidos, 10016
- New York University School of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19134
- St. Christopher's Hospital for Children
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105
- St. Jude Children's Research Hospital
-
-
-
-
-
Cape Town, Sudáfrica, 7925
- Desmond Tutu HIV Research Centre
-
Dundee, Sudáfrica, 3000
- Mpati Medical Center
-
Johannesburg, Sudáfrica, 2092
- Clinical HIV Research Unit
-
Soweto, Sudáfrica, 2013
- Perinatal HIV Research Unit
-
Stellenbosch, Sudáfrica, 7602
- University of Stellenbosch
-
-
Gauteng
-
Johannesburg, Gauteng, Sudáfrica, 2112
- Rahima Moosa Mother and Child Hospital (Wits)
-
-
Kwazulu-Natal
-
Durban, Kwazulu-Natal, Sudáfrica, 4001
- Dr Latiff Private Practice
-
-
-
-
-
Bangkok, Tailandia, 10330
- The HIV Netherlands Australia Thailand Research collaboration (HIV-NAT)
-
Bangkok, Tailandia, 10700
- Siriraj Hospital, Mahidol University
-
Chon Buri, Tailandia, 20110
- Queen Savang Vadhana Memorial Hospital
-
Khon Kaen, Tailandia, 40002
- Srinakarind Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- 12 years to < 18 years of age at baseline
- Able to give written assent prior to any screening evaluations
- Parent or guardian able to give written informed consent prior to any screening evaluations and willing to comply with study requirements
- Plasma HIV-1 RNA levels of ≥ 1,000 copies/mL
- CD4+ cell count > 100 cells/µL
- Weight ≥ 35 kg (77 lbs)
- Screening genotype report must show sensitivity to FTC and TDF
- Able to swallow oral tablets
- Adequate renal function
- Clinically normal ECG
- Documented screening for active pulmonary tuberculosis per local standard of care within 6 months of a screening visit
- Hepatic transaminases ≤ 5 x upper limit of normal
- Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
- Individuals with a positive Hepatitis B surface antigen screening test can participate in the study, providing that alternate therapy (other than TDF) for chronic Hepatitis B infection is available as a part of local standard of care
- Adequate hematologic function
- Negative serum pregnancy test for all females
- Males and females of childbearing potential must agree to utilize highly effective contraception methods while on study treatment or agree to abstain from heterosexual intercourse throughout the study period and for 30 days following the last dose of study drug
- Males must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 30 days following discontinuation of investigational medicinal product
- Must be willing and able to comply with all study requirements
- Life expectancy ≥ 1 year
Key Exclusion Criteria:
- A new AIDS-defining condition diagnosed within the 30 days prior to screening
- Prior treatment with any approved or investigational or experimental anti HIV-1 drug for any length of time (other than that given for prevention of mother-to-child transmission)
- Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit
- Anticipated to require rifamycin treatment for mycobacterial infection while participating in the study. Note: prophylactic Isoniazid (INH) therapy for latent tuberculosis (TB) treatment is allowed.
- Individuals experiencing decompensated cirrhosis
- Pregnant or lactating females
- Have any serious or active medical or psychiatric illness which would interfere with treatment, assessment, or compliance with the protocol. This would include uncontrolled renal, cardiac, hematological, hepatic, pulmonary, endocrine, central nervous, gastrointestinal, vascular, metabolic, immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment within 30 days prior to the study dosing.
- Current alcohol or substance abuse that will potentially interfere with compliance
- Have history of significant drug sensitivity or drug allergy
- Known hypersensitivity to the study drugs, the metabolites or formulation excipients
- Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening or expected to receive these agents during the study
- A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma
- Have previously participated in an investigational trial involving administration of any investigational agent within 30 days prior to the study dosing
- Participation in any other clinical trial without prior approval from sponsor is prohibited while participating in this trial
- Receiving ongoing therapy with any disallowed medications, including drugs not to be used with EVG, COBI, FTC, TDF or individuals with any known allergies to the excipients of EVG/COBI/FTC/TDF STR tablets
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: EVG/COBI/FTC/TDF
Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
|
150/150/200/300 mg STR administered orally once daily with food
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG
Periodo de tiempo: Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
|
Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
Incidence of Treatment-Emergent Serious Adverse Events (SAEs) and All Treatment-Emergent Adverse Events (AEs)
Periodo de tiempo: Up to Week 48 plus 30 days
|
Up to Week 48 plus 30 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
For Part A, PK Parameter: Ctau of EVG, FTC, Tenofovir (TFV), and COBI
Periodo de tiempo: Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
Ctau is defined as the observed drug concentration at the end of the dosing interval.
|
Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
For Part A, PK Parameter: Cmax of EVG, FTC, TFV, and COBI
Periodo de tiempo: Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
Cmax is defined as the maximum concentration of drug.
|
Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
For Part A, PK Parameter: AUCtau of FTC, TFV, and COBI
Periodo de tiempo: Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
|
Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10
|
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 24 and 48 as Defined by the FDA Snapshot Analysis
Periodo de tiempo: Weeks 24 and 48
|
Weeks 24 and 48
|
|
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Weeks 24 and 48 as Defined by the FDA Snapshot Analysis
Periodo de tiempo: Weeks 24 and 48
|
Weeks 24 and 48
|
|
Change From Baseline in Plasma log10 HIV-1 RNA at Weeks 24 and 48
Periodo de tiempo: Baseline; Weeks 24 and 48
|
Baseline; Weeks 24 and 48
|
|
Cambio desde el inicio en el recuento de células CD4+ en las semanas 24 y 48
Periodo de tiempo: Base; Semanas 24 y 48
|
Base; Semanas 24 y 48
|
|
Change From Baseline in CD4 Percentage at Weeks 24 and 48
Periodo de tiempo: Baseline; Weeks 24 and 48
|
Baseline; Weeks 24 and 48
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Gaur A, Fourie J, Chokephaibulkit K, Bekker L-G, Yin X, Custodio J, Bennett S, Cheng A, Quirk E. Pharmacokinetics, Efficacy and Safety of an Integrase Inhibitor-Based Single-Tablet Regimen in HIV-Infected Treatment-Naïve Adolescents. 21st Conference on Retroviruses and Opportunistic Infections (CROI). March 2014. Boston, MA, USA
- Chokephaibulkit K, Gaur A, Fourie J, Bekker L-G, Shao Y, Custodio J, Bennett S, Cheng A, Quirk E. Safety and Efficacy of the Integrase Inhibitor-Based Stribild Single-Tablet Regimen in HIV-Infected Adolescents Through 24 Weeks of Treatment. 20th International AIDS Conference. July 2014. Melbourne, Australia
- Porter DP, Bennett S, Quirk E, Miller MD, White KL. Lack of Emergent Resistance in HIV-1-Infected Adolescents on Elvitegravir-Based STRs. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). February 2015. Seattle, WA, USA
- Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Chokephaibulkit K, Fourie J, Bekker LG, Shao Y, Bennett S, Quirk E. Changes in renal laboratory markers and bone mineral density in treatment-naïve HIV-1-infected adolescents initiating INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF). 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention. July 2015. Vancouver, Canada
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Enfermedades del sistema inmunológico
- Enfermedades de virus lentos
- Infecciones por VIH
- Síndrome de inmunodeficiencia adquirida
- Síndromes de deficiencia inmunológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Agentes Anti-VIH
- Agentes antirretrovirales
- Elvitegravir, cobicistat, emtricitabina, tenofovir disoproxil fumarato combinación de fármacos
Otros números de identificación del estudio
- GS-US-236-0112
- 2015-000313-40 (Número EudraCT)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán
Ensayos clínicos sobre EVG/COBI/FTC/TDF
-
Gilead SciencesTerminadoInfecciones por VIH | VIHCanadá, Estados Unidos, España, Puerto Rico, Francia, Suiza, Australia, Alemania, Reino Unido, Suecia, Brasil, Austria, Tailandia, Países Bajos, Bélgica, República Dominicana, Portugal, Italia, Dinamarca, México
-
Juan A. ArnaizDesconocido
-
Fundacion SEIMC-GESIDATerminado
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... y otros colaboradoresTerminadoHipoestrogenismo | Desmineralización ósea | Lesión renal subclínica | Microarquitectura óseaUganda
-
Yale UniversityTerminadoInfecciones por VIHEstados Unidos
-
Duke UniversityTerminado
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLCTerminado
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development... y otros colaboradoresTerminadoProfilaxis del Virus de Inmunodeficiencia Humana (VIH)Estados Unidos
-
Azienda Ospedaliera San Gerardo di MonzaGilead SciencesTerminadoCalidad de vida | Infección por VIH-1 | Cognición deteriorada | Sueño de mala calidad | Depresión ansiedadItalia
-
ANRS, Emerging Infectious DiseasesUniversity of KwaZulu; Africa Centre For Health and Population StudiesTerminadoImpacto de la iniciación guiada de TARV inmediata versus sudafricana en la incidencia del VIH (TasP)Infección por VIHSudáfrica